Angioedema with normal laboratory values: The next step

Current Allergy and Asthma Reports

Volumn 13, Issue 5, 2013, Pages 563-570

  Sher, Janelle ^a   Davis Lorton, Mark ^a  

^a WINTHROP UNIVERSITY   (United States)

Author keywords

Angioedema; Bradykinin; Diagnosis; Drug induced angioedema; Estrogen; Hereditary angioedema; Hereditary angioedema with normal C1 inhibitor; Idiopathic angioedema; Normal complement levels; Pathophysiology; Treatment

Indexed keywords

ADRENALIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C4; CONTRAST MEDIUM; CORTICOSTEROID; DANAZOL; DESLORATADINE; DESOGESTREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ECALLANTIDE; ESTROGEN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FIBRINOLYTIC AGENT; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICATIBANT; PROGESTERONE; PROTON PUMP INHIBITOR; PSYCHOTROPIC AGENT; SITAGLIPTIN; TRANEXAMIC ACID; UNINDEXED DRUG; VILDAGLIPTIN;

ABNORMAL LABORATORY RESULT; ALGORITHM; ALLERGIC DISEASE; ANAMNESIS; ANGIONEUROTIC EDEMA; ARTICLE; AUTOIMMUNE DISEASE; CAPILLARY LEAK SYNDROME; CLINICAL FEATURE; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ESTROGEN ACTIVITY; HEALTH CARE PERSONNEL; HUMAN; IDIOPATHIC DISEASE; IMMUNOPATHOGENESIS; LABORATORY TEST; MEDICAL EXAMINATION; MEDICAL INFORMATION; NOMENCLATURE; NONHUMAN; NORMAL VALUE; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; URTICARIA;

ANGIOEDEMA; COMPLEMENT C1 INACTIVATOR PROTEINS; DIAGNOSIS, DIFFERENTIAL; HUMANS;

EID: 84885179091     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-013-0383-7     Document Type: Article

References (59)

1. Kaplan AP. Angioedema. World Allergy Organ J. 2008;1:103-13.
2. •• Sanchez-Borges M, Asero R, Ansotegui IJ, Baiardini I, Bernstein JA, Canonica GW, et al. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ J. 2012;5:125-47. These are current evidence-based guidelines put forth by the World Allergy Organization.
3. Davis 3rd AE. The pathophysiology of hereditary angioedema. Clin Immunol. 2005;114:3-9.
4. Zuraw BL. Current and future therapy for hereditary angioedema. Clin Immunol. 2005;114:10-6.
5. Agostoni A, Aygoren-Pursun E, Binkley KE, Blanch A, Bork K, Bouillet L, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114:S51-S131.
6. Zingale LC, Beltrami L, Zanichelli A, Maggioni L, Pappalardo E, Cicardi B, et al. Angioedema without urticaria: a large clinical survey. CMAJ. 2006;175:1065-70.
7. Greenberger PA. Anaphylactic and anaphylactoid causes of angioedema. Immunol Allergy Clin North Am. 2006;26:753-67.
8. • Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, et al. International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol Off J Can Soc Allergy Clin Immunol. 2010;6:24. This is an excellent review on the approach to the diagnosis and management of hereditary angioedema.
9. Zingale LC, Castelli R, Zanichelli A, Cicardi M. Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management. Immunol Allergy Clin North Am. 2006;26:669-90.
10. Campo P, Fernandez TD, Canto G, Mayorga C. Angioedema induced by angiotensin-converting enzyme inhibitors. Curr Opin Allergy Clin Immunol. 2013;13:337-44.
11. Clarkson B, Thompson D, Horwith M, Luckey EH. Cyclical edema and shock due to increased capillary permeability. American J Medicine. 1960;29:193-216.
12. Fischer R, Ostendorf B, Richter J, Schneider M. Hypovolemic shock associated with generalized edema: paroxysmal non-hereditary angioedema (Clarkson syndrome). Dtsch Med Wochenschr. 2000;125:427-8.
13. Binkley KE, Davis 3rd A. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol. 2000;106:546-50.
14. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet. 2000;356:213-7.
15. •• Zuraw BL, Bork K, Binkley KE, Banerji A, Christiansen SC, Castaldo A, et al. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc. 2012;33 Suppl 1:S145-56.
16. Bork K, Gul D, Hardt J, Dewald G. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am J Med. 2007;120:987-92.
17. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun. 2006;343:1286-9.
18. Cohen AJ, Laskin C, Tarlo S. C1 esterase inhibitor in pregnancy. J Allergy Clin Immunol. 1992;90:412-3.
19. Martin L, Degenne D, Toutain A, Ponard D, Watier H. Hereditary angioedema type III: an additional French pedigree with autosomal dominant transmission. J Allergy Clin Immunol. 2001;107:747-8.
20. Ogston D, Walker J, Campbell DM. C1 inactivator level in pregnancy. Thromb Res. 1981;23:453-5.
21. Bork K. Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor. Allergy, Asthma, and Clinical Immunology: official journal of the Canadian Society of Allergy and. Clin Immunol. 2010;6:15.
22. Bork K, Gul D, Dewald G. Hereditary angio-oedema with normal C1 inhibitor in a family with affected women and men. Br J Dermatol. 2006;154:542-5.
23. Vitrat-Hincky V, Gompel A, Dumestre-Perard C, Boccon-Gibod I, Drouet C, Cesbron JY, et al. Type III hereditary angio-oedema: clinical and biological features in a French cohort. Allergy. 2010;65:1331-6.
24. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine. 1992;71:206-15.
25. Bouillet L, Longhurst H, Boccon-Gibod I, Bork K, Bucher C, Bygum A, et al. Disease expression in women with hereditary angioedema. Am J Obstet Gynecol. 2008;199(484):e1-4.
26. Caballero T, Farkas H, Bouillet L, Bowen T, Gompel A, Fagerberg C, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. 2012;129:308-20.
27. Czaller I, Visy B, Csuka D, Fust G, Toth F, Farkas H. The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. European J Obstet Gynecol Reprod Biol. 2010;152:44-9.
28. Martinez-Saguer I, Rusicke E, Aygoren-Pursun E, Heller C, Klingebiel T, Kreuz W. Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Am J Obstet Gynecol. 2010;203(131):e1-7.
29. Halbmayer WM, Hopmeier P, Mannhalter C, Heuss F, Leodolter S, Rubi K, et al. C1-esterase inhibitor in uncomplicated pregnancy and mild and moderate preeclampsia. Thromb Haemost. 1991;65:134-8.
30. Picone O, Donnadieu AC, Brivet FG, Boyer-Neumann C, Fremeaux-Bacchi V, Frydman R. Obstetrical complications and outcome in two families with hereditary angioedema due to mutation in the F12 gene. Obstet Gynecol Int. 2010;2010:957507.
31. Bouillet L, Ponard D, Rousset H, Cichon S, Drouet C. A case of hereditary angio-oedema type III presenting with C1-inhibitor cleavage and a missense mutation in the F12 gene. Br J Dermatol. 2007;156:1063-5.
32. Campbell SJ, Mackie IJ, Robinson GE, Machin SJ. Contact factor mediated fibrinolysis is increased by the combined oral contraceptive pill. Br J Obstet Gynaecol. 1993;100:79-84.
33. Fossum S, Hoem NO, Gjonnaess H, Briseid K. Contact activation factors in plasma from women on estrogen replacement therapy after ovariohysterectomy. Thromb Res. 1999;93:161-70.
34. Fossum S, Hoem NO, Johannesen S, Korpberget M, Nylund E, Sandem S, et al. Contact factors in plasma from women on oral contraception - significance of factor XI for the measured activity of factor XII. Thromb Res. 1994;74:477-85.
35. Gordon EM, Douglas JG, Ratnoff OD, Arafah BM. The influence of estrogen and prolactin on Hageman factor (factor XII) titer in ovariectomized and hypophysectomized rats. Blood. 1985;66:602-5.
36. Ratnoff OD. The hormonal control of the synthesis of Hageman factor (factor XII). Phenomenology and science: friends or foes? J Lab Clin Med. 1991;117:343.
37. Zuraw BL. Diagnosis and management of hereditary angioedema: an American approach. Transfus Apher Sci. 2003;29:239-45.
38. Agostoni A, Cicardi M. Drug-induced angioedema without urticaria. Drug Saf. 2001;24:599-606.
39. Sarkar P, Nicholson G, Hall G. Brief review: angiotensin converting enzyme inhibitors and angioedema: anesthetic implications. Can J Anaesth. 2006;53:994-1003.
40. Warner KK, Visconti JA, Tschampel MM. Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema. Ann Pharmacother. 2000;34:526-8.
41. Vleeming W, van Amsterdam JG, Stricker BH, de Wildt DJ. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf. 1998;18:171-88.
42. Haymore BR, Yoon J, Mikita CP, Klote MM, DeZee KJ. Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis. Ann Allergy Asthma Immunol. 2008;101:495-9.
43. Banerji A, Clark S, Blanda M, LoVecchio F, Snyder B, Camargo Jr CA. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol. 2008;100:327-32.
44. Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am. 2006;26:725-37.
45. Gainer JV, Stein CM, Neal T, Vaughan DE, Brown NJ. Interactive effect of ethnicity and ACE insertion/deletion polymorphism on vascular reactivity. Hypertension. 2001;37:46-51.
46. Sondhi D, Lippmann M, Murali G. Airway compromise due to angiotensin-converting enzyme inhibitor-induced angioedema: clinical experience at a large community teaching hospital. Chest. 2004;126:400-4.
47. Gosmanov AR, Fontenot EC. Sitagliptin-associated angioedema. Diabetes Care. 2012;35:e60.
48. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009;54:516-23.
49. Skalli S, Wion-Barbot N, Baudrant M, Lablanche S, Benhamou PY, Halimi S. Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report. Diabet Med. 2010;27:486-7.
50. Frigas E, Nzeako UC. Angioedema. Pathogenesis, differential diagnosis, and treatment. Clin Rev Allergy Immunol. 2002;23:217-31.
51. Bork K, Wulff K, Hardt J, Witzke G, Staubach P. Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol. 2009;124:129-34.
52. Bell CG, Kwan E, Nolan RC, Baumgart KW. First molecular confirmation of an Australian case of type III hereditary angioedema. Pathology. 2008;40:82-3.
53. Prieto A, Tornero P, Rubio M, Fernandez-Cruz E, Rodriguez-Sainz C. Missense mutation Thr309Lys in the coagulation factor XII gene in a Spanish family with hereditary angioedema type III. Allergy. 2009;64:284-6.
54. Bouillet L, Boccon-Gibod I, Ponard D, Drouet C, Cesbron JY, Dumestre-Perard C, et al. Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks. Ann Allergy Asthma Immunol. 2009;103:448.
55. Herrmann G, Schneider L, Krieg T, Hunzelmann N, Scharffetter-Kochanek K. Efficacy of danazol treatment in a patient with the new variant of hereditary angio-oedema (HAE III). Br J Dermatol. 2004;150:157-8.
56. Smith Jr SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2006;47:2130-9.
57. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:S1-290.
58. Beltrami L, Zanichelli A, Zingale L, Vacchini R, Carugo S, Cicardi M. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. J Hypertens. 2011;29:2273-7.
59. Sachdeva S, Gupta V, Amin SS, Tahseen M. Chronic urticaria. Indian J Dermatol. 2011;56:622-8.